Redeye leaves a comment on the Q1 report from Egetis Therapeutics released earlier this morning.
Recyctec publicerade idag den 26 april bolagets delårsrapport för Q1-22.
Tjänsteföretaget Coor väntas redovisa en tillväxt på omkring 20 procent under första kvartalet, driv...
Redeye raises the fair value of M.O.B.A. Network on the back of strong underlying growth and a stron...
Redeye comments on GiG ahead of its Q1-results (due 10 May) where we expect focus to be on Sportnco ...
Redeye adjusts its fair value range with a downward bias but continues to see meaningful upside to t...
SportnCo included in estimates from Q2’22 Change in our P&L structure – ‘22e adj.
Redeye raises its Base Case and forecasts slightly for ADDvise following a solid Q1 report.
Raute reports Q1 results on Apr 29. We continue to expect only break-even EBIT for this year.
Q1’22 organic rev. growth of 6% (cons. 8%) FY’22 guidance reiterated, indicating back-end loaded FY...
But lower gross margin caused -8% adj. EBITA vs ABGe Demand is good but supply chain is challenging ...
Redeye sees a mixed Q1 report from Proact, with solid organic growth in both Cloud and Support being...
Utvecklingen går framåt och vi på Analysguiden räknar med att samtliga av Biotechs tre projekt under...
CapMan reports its Q1 results on April 28th. We expect rather good results but have lowered our prof...
Q1 earnings will be affected by destocking and high costs.
We take a more cautious view ahead of Atria's Q1 results due on 3 May.
Stockholm-oriented names highlight pick-up in the city Tougher but so far manageable funding conditi...
Q1 report due on Wednesday, 18 May Environmental permit application was submitted in Q1 Company expe...
Idag tillkännagav GPX Medical att den kliniska forskaren och neonatologen Jurate Panaviene presenter...
Q1 report due on Wednesday 27 April Strong series production, softer equipment sales 21x ’22e EV/EBI...
